Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Maybe the room was designed for 15, so the crowd was "big".
So V allows increased risk of other bad stuff to happen. LMAO
So don't save someone from a fire because they might get in an auto accident next week.
Please give me the chance to take the risk.
Might have been a BO premium when it was in the $22-24 range.
I think its backed off of that and trades at some forward multiple of 1 or 2 year earnings for a GIA.
My personal opinion only of course.
CBB: "stock price would lose its current buyout premium".
Who said there is a buyout premium baked in right now?
JB: Don't forget the effect of current/foretasted revenue/earnings growth% on the PPS. During periods of max revenue growth, the PPS will likely get an additional multiple kick. MHO
HR
No buyout in 2019. My vote.
10% chance in 2020.
BB: Wider audience..direct to the end users.
Raf: Why has JT constantly indicated "Standard Review" is probable? Probably because he has the answer to your questions. But it doesn't mean he doesn't have faith in the ultimate success of V.
Re PPS: Nothing revenue and earnings ramp-up proof won't cure!
PPS has been trading in rarefied air with respect to earnings IMO.
All these papers, seminars, approvals, etc are nice, but until the earnings "inflection point" AKA "hockey stick" actually occurs, we drift IMO. My guess is 2020 Q3 for that, but I would like to be pleasantly surprised.
I know, I know, I will now be asked to define how we identify the "inflection point"...:} Maybe breaking $24 will give an indication.
HR
Study: I concur with your evaluations.
I too am hoping for GIA and the benefits of PPS 4-5 years from now; If a buyout in the price range you suggest does occur in the next 12 months, hopefully there will be some CVR to pad the future.
HR
It's still early in the Amarin story. Think 2023.
Tasty first of all my apologies for referring to you as flying fish I meant no disrespect to either of you just a simple mistake.
Secondly I see a different Amarin in 2023 one which is broader. That's why I use that approach.
Also I see many other companies and stocks in a similar situation which trade at a price-earnings at or around the%growth.
I guess we'll be seeing in 4 years. Peace. Herbie Ray
Looks like a good move up till now at least. I'm also a long-term holder but I'm fresh out of dry powder.
FFS, you're missing my point. The fact is that many stocks in their growth phase with revenues and earning growth of 50 to 60% trade at a PE of 50 or higher I can name hundreds.
Therefore once Amarin gets to that stage I'm looking for similar PE ratios
2023 outlook quote from smarteranalyst(Ben Mahaney)May6:
"At $18 a share and 40 times estimated earnings two-years-from-now, Amarin stock doesn't look exactly cheap today. Still, with analysts predicting more than $2 a share in earnings by 2023, the stock's valuation looks increasingly more palatable the farther out you look."
So assuming $2/sh earnings and 50-60% earnings and revenue growth in 2023, what would be expected for a PE multiple? Would 40-60 be unrealistic. I don't think so, which is why I have my current outlook eyes on 2023.
I do it because I can and it's fun.
It will all end 2 seconds after you sell all your shares in frustration. At that point either a buyout will be announced or FDA approval will be announced.
MATINAS BIOPHARMA has been pumping their trial drug based on Reduce-it outcome. Just wondering if Amarin can stop this in the same way they are stopping Coromega and (presumably) Omax.
Maybe not worth the effort?
Any thoughts.
TIA, HR
Bernie Sanders walks into a bar and says: "Free drinks for everyone!.... who's wants to pay for them?"
Raf: from JT's question and answers Wednesday:
With respect to the EU, our priority has been to make sure we do the U.S. process right and that has been consuming here with regard to the very large submission we sent in to the FDA. And fortunately our partners in Canada were able to piggyback that one pretty directly. Europe is a bit more complicated. There are a number of considerations there, country by country, and EU overall, there is also a different role from a regulatory side, and from a pricing side, and we are increasingly turning our attention to that. Now that the submission is filed in the U.S., and we’ve got a little bit of a window here, before we are likely hear back from the FDA at the 60-day to 74-day time frame. So we’re using some of that time to advance of our planning for an EU filing.
Wow! Thanks Raf! Chock full of goodies!
JT gave EU perspective during the CC Q&A. The rationale for not hitting EU hard right now is right there.
bfost: Agree 100%!
Bio: obviously no company can lose$$ indefinitely! Its the phase of growth development that makes the difference in what we are talking about.
Peace.
HR
Then how do you explain Tesla? There's a big difference between an emerging company and a brick-and-mortar company like GE
It's all about forecasted Revenue growth. There are many companies trading out there in the stratusphere PPS that are losing money but because they have a huge potential for Revenue growth they're up where they are
Entrails are exactly what TA charts show you if you know what to look for.
Points out at what price levels the predators that cause the entrails lie.
Kind of what our Native Americans used to spot their prey and predators. Found the dead bodies.
well you get the point.
....or do you?
Lemme see now, I think I heard of one possibility of a bolt-on bantered around this board! :}
Previous guidance of $0 EBIDA in 2019.
Wonder if revised guidance (if any) will confirm.
V: Intelligence is in the mind of the beholder. It involves what one chooses to concentrate on.
So 2023 irritates you? Well this constant board talk about buyouts and obsession with short term swings irritates ME!
You want an explanation? I'm sure it won't satisfy you but here it is anyway: I am trying to plant the seed on this board of looking long term rather than watching the short term manipulation and trying to decipher the reason behind every short sale and up and down tick. That to me is sick.
I assume GIA, and 2023 is where I see the maximum "product" of Revenue and Revenue Growth rate. (R*dR/dt). This "product" is capable of producing a large P/E multiple, likely 20 but possibly as high as 40-50 or even higher. One sees it in the PPS of the high growth phase of many stocks.
So therefore I sit back and think 2023, and occasionally I encourage others to do the same. Sorry it irritates you. Perhaps you should take a look inside and find out the reason for that.
Peace
HR
In 2023 it will he insignificant.
Think 2023. At that time you will look back and wonder what the heck you worried about.
Shoild show up one way or another in the financial releases.
Right.. lump sum payment or % royalties of the Coromega O3 sales?
I simply missed it thanks HG. I do understand it now that I see it.
I asked this before but I don't think I got an answer
Are revenues based on sales to distributors or retail scripts?
Or before,,,"BY day 60".
Probably
MP: you seem like a relatively intelligent person. So how can you in good conscience assume what a person knows from their current role in Life or their job title?
If that is any indication of how you compartmentalize and or judge people on this board who you don't even know or haven't dealt with or haven't even met, then you're opinions are already a-priory biased.
I suggest you do some research on a 1950s actress named Hedy Lamarr. The fact that she was a beautiful female sexy actress belies the fact that she was one of the mothers of radar and the internet.
AAAA11111!!!!!!